Novel cis‐Pt(II) Complexes with Alkylpyrazole Ligands: Synthesis, Characterization, and Unusual Mode of Anticancer Action
Open Access
- 1 January 2022
- journal article
- research article
- Published by Wiley in Bioinorganic Chemistry and Applications
- Vol. 2022 (1) , 1717200
Abstract
One concept of improving anticancer effects of conventional platinum‐based antitumor drugs consists of conjugating these compounds with other biologically (antitumor) active agents, acting by a different mechanism. Here, we present synthesis, physicochemical characterization, biological effects, and mechanisms of action of four new analogs of conventional cisplatin, namely, cis‐Pt(II) complexes containing either methyl or ethyl pyrazole N‐donor ligands and chlorido or iodido ligands. It is noteworthy that while chlorido complexes display activity in a variety of cancer cell lines comparable to cisplatin, iodido complexes are considerably more potent due to their enhanced hydrophobicity and consequently enhanced cellular accumulation. Moreover, all of the studied Pt(II) alkylpyrazole complexes display a higher selectivity for tumor cells and effectively overcome the acquired resistance to cisplatin. Further results focused on the mechanism of action of the studied complexes and showed that in contrast to cisplatin and several platinum‐based antitumor drugs, DNA damage by the investigated Pt(II)‐alkylpyrazole complexes does not play a major role in their mechanism of action. Our findings demonstrate that inhibition of the tubulin kinesin Eg5, which is essential for forming a functional mitotic spindle, plays an important role in their mechanism of antiproliferative action.Keywords
Funding Information
- Russian Foundation for Basic Research (19-53-26002)
This publication has 62 references indexed in Scilit:
- Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cellsJBIC Journal of Biological Inorganic Chemistry, 2013
- Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side EffectsCancers, 2011
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- Kinetic Cell-Based Morphological Screening: Prediction of Mechanism of Compound Action and Off-Target EffectsChemistry & Biology, 2009
- To step or not to step? How biochemistry and mechanics influence processivity in Kinesin and Eg5Current Opinion in Cell Biology, 2007
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- KINETIC STUDY ON THE REACTION OF CISPLATIN WITH METALLOTHIONEINDrug Metabolism and Disposition, 2003
- Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based ScreenScience, 1999
- Platination Pathways for Reactions of Cisplatin with GG Single‐Stranded and Double‐Stranded DecanucleotidesAngewandte Chemie International Edition, 1995
- Coordination compounds of platinum(II) and palladium(II) with pyrazole as a ligand. New synthetic procedures and characterisationTransition Metal Chemistry, 1980